Tahor

Phase 2Small molecule

IInstitut National de la Santé Et de la Recherche Médicale, France

Tahor is one of 5 small molecule programs targeting Spastic paraplegia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spastic ParaplegiaActive, not recruiting

Spastic ParaplegiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Spastic Paraplegia

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Opfolda

1 3

Calcium Folinate

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

1 4

Tahor

IInstitut National de la Santé Et de la Recherche Médicale, France

Phase 2

1 5

MELPIDA

EElpida Therapeutics SPC

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spastic paraplegia1 trial

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT02314208·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tahor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tahor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tahor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut National de la Santé Et de la Recherche Médicale, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitut National de la Santé Et de la Recherche Médicale, France

Tahor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spastic paraplegia1 trial

References

Drug Info

Quick Facts

Related News